In a previous study, we reported an increasing trend in the use of first-line programmed death receptor-1/programmed death-ligand 1 (PD-(L)1) inhibitor-based regimens for patients with advanced NSCLC from 2017 to 2020 [5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.